Búsqueda de Publicación - Prisma - Unidad de Bibliometría

Publicaciones en la fuente LANCET INFECTIOUS DISEASES

Tipo Año Título Fuente
Artículo2024Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial.LANCET INFECTIOUS DISEASES
Artículo2024Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trialLANCET INFECTIOUS DISEASES
Artículo2021Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort studyLANCET INFECTIOUS DISEASES
Editorial2021The value of open-source clinical science in pandemic response: lessons from ISARICLANCET INFECTIOUS DISEASES
Artículo2020Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort studyLANCET INFECTIOUS DISEASES
Artículo2020Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum β-lactamase-producing Escherichia coli in the community: an interrupted time-series analysisLANCET INFECTIOUS DISEASES
Artículo2018Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosisLANCET INFECTIOUS DISEASES
Artículo2018Surveillance for control of antimicrobial resistanceLANCET INFECTIOUS DISEASES
Letter2017Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae ReplyLANCET INFECTIOUS DISEASES
Artículo2017Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort studyLANCET INFECTIOUS DISEASES
Letter2016Early initiation of antiretroviral therapy: Debate over?LANCET INFECTIOUS DISEASES
Letter2014Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIVLANCET INFECTIOUS DISEASES